TABLE 1

Influence of ABPC or CA treatment on bile acid composition in the small intestinal lumen

VehicleABPCUntreatmentCA
Primary bile acid (μmol)
    βMCA0.32 ± 0.32N.D.0.40 ± 0.080.02 ± 0.02***
    TβMCA3.43 ± 1.576.63 ± 0.60**3.40 ± 1.040.40 ± 0.22**
    UDCAN.D.N.D.N.D.N.D.
    TUDCA0.10 ± 0.070.32 ± 0.03***0.14 ± 0.060.06 ± 0.02*
    CA0.54 ± 0.46N.D.0.64 ± 0.301.14 ± 1.02
    TCA3.05 ± 0.865.39 ± 0.42**3.20 ± 0.5012.38 ± 3.98***
    CDCA0.01 ± 0.010.01 ± 0.01N.D.N.D.
    TCDCA0.04 ± 0.030.17 ± 0.04***0.02 ± 0.02N.D.
    Total7.49 ± 1.8712.50 ± 0.95**7.80 ± 1.8214.00 ± 4.78*
Secondary bile acid (μmol)
    DCA0.04 ± 0.06N.D.0.02 ± 0.020.24 ± 0.38
    TDCA0.21 ± 0.09N.D.0.06 ± 0.023.96 ± 1.26***
    LCAN.D.N.D.N.D.N.D.
    TLCAN.D.N.D.N.D.N.D.
    Total0.26 ± 0.09N.D.0.08 ± 0.024.18 ± 1.14***
    Total bile acid7.74 ± 1.8112.50 ± 0.95**7.88 ± 1.8018.20 ± 5.86*
  • Data are shown as mean ± S.D. (n = 4–5). N.D. represents <0.01 μmol. Significant differences from the vehicle-treated group are expressed with an asterisk (*, p < 0.05; **, p < 0.01; ***, p < 0.001).